Khavinson peptide bioregulators: what the research is and how strong it is

"Peptide bioregulators" is the name a group of Russian researchers gave to a family of very short synthetic peptides, most of them two to four amino acids long [1]. Several are now sold online as research materials, so it is worth asking what the published evidence shows, who produced it and how far others have checked it. This guide covers those questions. It does not describe any use in people.

Origin

The short peptides were created at the St. Petersburg Institute of Bioregulation and Gerontology [2]. Vladimir Khavinson and colleagues describe two stages: polypeptide extracts were first isolated from animal organs, and short peptides of two to four amino acids were then designed and synthesized [1]. Epitalon, for example, was synthesized on the basis of the amino acid composition of epithalamin, an extract of bovine pineal gland [11]. An independent 2026 review describes the two as chemically distinct and assesses epithalamin studies separately from those of the synthetic tetrapeptide [9].

The main compounds

The group's 2021 review lists these sequences in one-letter amino acid code [1]:

• Epitalon: AEDG (Ala-Glu-Asp-Gly) [1]
• Vilon: KE (Lys-Glu) [1]
• Pinealon: EDR [1]
• Cardiogen: AEDR [1]
• Bronchogen: AEDL [1]
• Testagen: KEDG [1]
• Vesugen: KED [1]
• Ovagen: EDL [1]
• Thymogen: EW [1]

Cortagen is Ala-Glu-Asp-Pro [12] and Livagen is Lys-Glu-Asp-Ala [13]. Thymalin is different in kind: it is described as a peptide complex rather than a single defined short peptide [10]. The 2021 review assigns each short peptide an organ or system it is said to regulate, such as lung cells for bronchogen and the cardiovascular system for cardiogen and vesugen, based largely on the authors' own studies [1].

The proposed mechanism

The group's central hypothesis is that short peptides enter cell nuclei, interact with histones and DNA, and so regulate gene expression [1]. Supporting work is mostly in cell culture and animals, for example the induction of interleukin-2 messenger RNA by vilon, epitalon and cortagen in mouse spleen cells [12]. These studies show biological activity in experimental systems; they do not show clinical benefit [9].

Human evidence

The most cited human study, published in 2003, followed 266 older people for six to eight years; some received the thymic extract thymalin or the pineal extract epithalamin during the first two to three years [3]. The authors reported lower mortality in the treated groups than in controls [3]. The abstract does not describe randomization or blinding, the interventions were organ extracts rather than the synthetic short peptides sold today, and the authors were from the developing institute [3]. The group's Russian-language clinical review summarizes its own long-term studies of preparations including thymalin, thymogen, vilon and epithalamin [20].

An independent 2026 review by US clinicians, whose authors declared no financial interest in the compounds, concluded that human evidence for epitalon is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa, and that no adequately powered randomized trial has established therapeutic efficacy [9]. It judged pharmacokinetic, dose-ranging and long-term safety data inadequate and described oncologic, immunogenicity and product-quality questions as unresolved [9].

Animal evidence: the lifespan example

Lifespan claims usually trace to rodent studies from the originating group and its collaborators. In one, 54 female mice per group received epitalon or saline from the age of three months until death [4]. Mean lifespan did not change, while the lifespan of the longest-lived 10% of survivors rose by 13.3% and maximum lifespan by 12.3% [4]. Total spontaneous tumour incidence did not change [4]. The study used one outbred strain and one sex, and we found no independent repetition of it.

How concentrated the literature is

We searched PubMed on 22 October 2026 to gauge this. Of 121 records mentioning epitalon, epithalon or epithalone in the title or abstract, 88 list V. Kh. Khavinson, V. N. Anisimov or N. S. Linkova as an author or the St. Petersburg institute as an affiliation [14]. Many of the remaining records come from other Russian groups, a long-running Georgian collaboration, or are reviews [14]. Studies run abroad sometimes still include the originating group: an Italian cell-line study of epitalon, vilon, thymogen, thymalin and chonluten lists Khavinson among its authors [10]. The count is approximate, because author and affiliation fields in older records are incomplete and Russian-language literature outside PubMed is not captured.

Independent replication

Independent laboratory work exists, but it is narrow and mostly about epitalon. A Brunel University London group, declaring no competing interests, reported that epitalon lengthened telomeres in normal human cells through increased hTERT expression and telomerase activity, and in breast cancer cell lines through alternative lengthening of telomeres [6]. That result is in line with the originating group's 2003 report of telomerase induction in human fetal fibroblasts [5], although it also shows an effect in cancer cells [6]. Groups in China and Korea have reported effects of epitalon on mouse oocytes ageing in culture and on bovine oocyte maturation and embryo development [7, 8]. We did not find independent replication of the lifespan results or of the human mortality findings.

Study quality in brief

• Most studies are small, in cells or rodents, and come from one research network [4, 14].
• Key human data concern organ extracts, not the synthetic short peptides [3, 9].
• Physicochemical and structural characterization of epitalon remains limited relative to the volume of biological studies [11].
• No adequately powered randomized trial has established efficacy for epitalon [9].

Regulatory status as of 22 October 2026

None of these peptides is an FDA-approved drug. In June 2026, FDA treated Prostamax as an unapproved new drug in a warning letter to a website that marketed it with health claims under a research-use-only label [18]. Epitalon's nomination for the 503A bulks list was withdrawn from Category 2, and FDA says it has not identified safety-related information for the proposed route and lacks the information to know whether it would cause harm [15]. In July 2026, FDA's compounding advisory committee discussed epitalon for the 503A list for insomnia [17]; FDA's briefing document said its literature search did not retrieve publications discussing efficacy in patients with insomnia and concluded that the criteria weighed against listing it [21]. FDA had posted no minutes or vote results for that meeting as of 22 October 2026 [17]. Epitalon was not in any 503A category in FDA's May 2026 document [16]. Belgian authorities identified epitalon in two illegal pharmaceutical preparations in 2015 [19]. The originating group describes clinical use of related preparations in Russia [20], but we could not confirm current registration status from a regulator's own records. Anti-doping rules are covered in the sport guide.

Bioregulator entries in this library

The library has entries for Bronchogen, Cardiogen, Cartalax, Chonluten, Cortagen, Livagen, Ovangen, Pancragen, Pinealon, Prostamax, Testagen, Thymagen, Thymalin, Vesugen and Vilon, and a separate entry for Epithalon. Each entry states its own evidence level.

Key points

• The bioregulators are short synthetic peptides developed at one St. Petersburg institute from earlier organ-extract work [1, 2].
• Most published studies come from the originating group and its collaborators [14].
• Independent work is limited to cell and oocyte studies of epitalon [6, 7, 8].
• No adequately powered randomized trial has established efficacy for epitalon [9].
• None is FDA-approved, and FDA has treated at least one as an unapproved new drug [18].